Poziotinib (CAS 1092364-38-9)
« Back to Anti-Cancer API
Poziotinib
CAS No. 1092364-38-9
波齐替尼
Chemical structure
| CAS No. | 1092364-38-9 |
|---|---|
| Synonyms | 1-[4-[[4-[(3,4-Dichloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-1-piperidinyl]-2-propen-1-one |
| Category | Anti-Cancer API / Anti-Cancer |
| Assay / Purity | 99% |
| Molecular Formula | C23H21Cl2FN4O3 |
| Molecular Weight | 491.3 |
| Melting Point | — |
| Boiling Point | — |
| Density | — |
| Flash Point | — |
| Appearance | Off-white to white solid powder |
Application and positioning
Poziotinib is an irreversible pan-HER tyrosine kinase inhibitor developed for EGFR and HER2 exon 20 insertion mutations. It is an investigational oral agent studied in non-small cell lung cancer with exon 20 insertion mutations. Laurand supplies it from audited Chinese production partners for pharmaceutical manufacturing and process development.
Quality and documentation
- Batch-specific Certificate of Analysis issued by the manufacturing site
- SDS/MSDS and specification sheet available on request
- Residual solvents and elemental impurities statements discussed per project
- For pharmaceutical manufacturing and R&D use only — not for direct administration
Packaging and handling
- Packed in double polyethylene-lined fibre drums; pack size confirmed at quotation
- Small quantities in sealed aluminium foil bags
- Palletised for air and sea freight; store dry, ventilated and protected from light
Related products
- Ribociclib Succinate (CAS 1374639-75-4)
- Ruxolitinib Phosphate (CAS 1092939-17-7)
- Temozolomide (CAS 85622-93-1)
- Vandetanib (CAS 443913-73-3)
Specifications shown are indicative. The final specification and documentation package are confirmed with the quotation.
Interested in this product?
Contact us for price, COA, MSDS and lead time — custom synthesis available.
Request a QuoteReference: CAS 1092364-38-9 · PubChem CID 25127713